BACKGROUND Sudden arrhythmic death syndrome (SADS) describes a sudden death with negative autopsy and
S
udden cardiac death (SCD) in the young is a devastating event. The annual incidence in the 1-to 35-year-old age group is estimated at 1.3 to 2.8 per 100,000 (1) . Autopsies in younger SCD victims lead to a diagnosis of structural cardiac disease in the majority. Yet, in 30% to 40% of cases, the cause remains elusive despite toxicological and histopathologic analysis (1, 2) . A proportion is expected to have suffered arrhythmic death and is referred to as succumbing from sudden arrhythmic death syndrome (SADS) (3, 4) . SADS is caused, in part, by primary electrical disorders such as long QT syndrome (LQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachycardia (CPVT), which are associated with a structurally normal heart (5,6).
Post-mortem testing of the genes underlying primary electrical disorders in cases of SADS (the "molecular autopsy") allows for ascertainment of the genetic cause (7, 8) . This may inform clinical and genetic evaluation of surviving relatives for SCD prevention (9) . Early case series focused on 4 main genes (KCNQ1, KCNH2, SCN5A, and RYR2). Table 1 ).
All the samples (i.e., cohorts 1, 2, and controls) were processed together. Low quality (Q <20, window size 5) reads/bases were trimmed and read quality assessed. High-quality reads were mapped to UCSC GRCh37/hg19 reference genome. Next-generation sequencing was used to mark duplicate reads, realign locally around indels, and recalibrate base quality scores according to best practices. Alignment summary metrics and coverage and callability metrics were generated. A base was considered "callable" if sequenced with minimum read depth ¼ 10x, base quality $20, and mapping quality $10. Target base callability of >90% was achieved in 98% of samples overall and in 92%, 95%, and 100% of samples from cohort 1, 2, and controls, respectively. Gene level callability is shown in Online (4, 25) . We then assessed the independent value of molecular autopsy and familial evaluation for a familial diagnosis.
RESULTS
Demographic and clinical characteristics of all subjects are presented in Table 1 . In total, 302 sudden of subjects. In 18%, a personal history of syncope or seizure was reported ( Figure 1C) . Importantly, 24 subjects had consulted a cardiologist or general practitioner regarding these symptoms. Twenty-one subjects (7%) were diagnosed either with epilepsy or had a previous history of epilepsy; 7 patients had type 1 diabetes mellitus and were being treated with insulin from early childhood or adolescence. Among the 105 female cases, 7 died suddenly during the post-partum period.
Genetic testing was performed (Central Illustration)
and there remained a total of 288 variants (MAF <1 in 10,000) in 55 different genes after variant filtering in the 302 SADS cases (Figure 2) . In 132 patients (44%), no rare variant was identified. Gene level callability indicated only minor deficits or differences in coverage between cohorts (Online Table 2 Nineteen pathogenic and 15 likely pathogenic variants resided in the primary electrical disorder genes, mainly RYR2, KCNQ1, KCNH2, and SCN5A. In the cardiomyopathy genes, we found 1 pathogenic variant in PLN and 5 likely pathogenic variants in TTN (n ¼ 3), PKP2 (n ¼ 1), and MYH7 (n ¼ 1). We identified a pathogenic variant in 4 subjects >35 years of age; KCNQ1, KCNH2, SCN5A, and RYR2.
Additionally, a likely pathogenic variant was identified in KCNQ1, KCNH2, TTN, and MYH7 in this age category. Furthermore, we found a pathogenic Values are median (interquartile range) or n/N (%). *Positive outcome was defined as a pathogenic or likely pathogenic variant per the ACMG guidelines (12) . †p values refer to the following comparison: positive genetic testing RYR2 (n ¼ 17) versus no positive RYR2 test (n ¼ 285). ‡Note missing data for these parameters and that percentages are based on nonmissing data. §Includes palpitations, shortness of breath, and chest pain.
ACMG ¼ American College of Medical Genetics; SADS ¼ sudden arrhythmic death syndrome; SCD ¼ sudden cardiac death. Table 4 ). Only RYR2 displayed an enrichment of rare variants in cases compared to controls at our pre-specified statistical significance threshold (p ¼ 6.5 Â 10 -4 ). To ensure that this result was not a consequence of systematic sequencing differences between cases and controls, we performed the same analysis using only rare synonymous variants, which did not uncover any differences (p ¼ 0.89).
Predictors of a positive genetic test are listed in Lahrouchi et al. 
DISCUSSION
We report, to our knowledge, the largest study of molecular autopsy and its clinical utility in a set of Post-Mortem Genetic Testing this study tested a comparable number of genes and also applied ACMG guidelines (10).
Our study found a likely pathogenic or pathogenic RYR2 variant in 17 patients (6%) in whom death occurred at a significantly younger age and more often during exercise or extreme emotion. This was consistent with our previous characterization of SADS cases that asserted that CPVT was an important cause of death in the young (29) . The predominant role of Indeed, the ratio of rare VUS to pathogenic or likely pathogenic cardiomyopathic variants was extremely unfavorable in our cohort ( Figure 2 ) and illustrated the need for careful and stringent adjudication. A small number of genotype-positive LQTS cases from New Zealand were not included in the study (13, 14) . Of these, only 3 would have been adjudicated as pathogenic or likely pathogenic by ACMG criteria and would not have affected the yield significantly. In addition, some exons were moderately covered (e.g., exon 1 of KCNQ1 and KCNH2 in cohort 1) (Online Table 3 ), but this was unlikely to have resulted in significant underestimation of the yield. Interpretation of variants in the small minority of nonCaucasian cases may have been hampered by the absence of large, ethnically specific population databases to which we could refer. Furthermore, we did not sequence genes currently associated with noncardiac disorders that predispose to sudden death.
CONCLUSIONS
Next-generation sequencing based molecular autopsy identified a 13% yield of clinically actionable 
